StoneCrest Wealth Management Inc. Has $2.49 Million Stock Holdings in Scholar Rock Holding Corporation $SRRK

StoneCrest Wealth Management Inc. lifted its position in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 24.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 59,003 shares of the company’s stock after purchasing an additional 11,671 shares during the quarter. StoneCrest Wealth Management Inc.’s holdings in Scholar Rock were worth $2,494,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Scholar Rock by 1.1% in the third quarter. Vanguard Group Inc. now owns 4,914,927 shares of the company’s stock valued at $183,032,000 after buying an additional 53,333 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Scholar Rock by 124.5% during the third quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock worth $169,289,000 after buying an additional 2,521,022 shares in the last quarter. Bellevue Group AG increased its holdings in shares of Scholar Rock by 10.1% during the third quarter. Bellevue Group AG now owns 3,244,537 shares of the company’s stock worth $120,827,000 after buying an additional 297,242 shares in the last quarter. Eventide Asset Management LLC raised its stake in shares of Scholar Rock by 9.5% in the second quarter. Eventide Asset Management LLC now owns 2,913,246 shares of the company’s stock valued at $103,192,000 after acquiring an additional 251,638 shares during the last quarter. Finally, Holocene Advisors LP acquired a new position in shares of Scholar Rock in the 3rd quarter worth approximately $91,670,000. 91.08% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, CFO Vikas Sinha sold 16,755 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total value of $715,438.50. Following the transaction, the chief financial officer owned 583,245 shares in the company, valued at $24,904,561.50. This trade represents a 2.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mo Qatanani sold 14,898 shares of the business’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $46.71, for a total value of $695,885.58. Following the sale, the insider directly owned 85,660 shares of the company’s stock, valued at $4,001,178.60. This represents a 14.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 207,464 shares of company stock valued at $9,157,423 over the last 90 days. Corporate insiders own 13.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on SRRK shares. Barclays increased their price target on Scholar Rock from $52.00 to $53.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 3rd. Wedbush boosted their price objective on Scholar Rock from $56.00 to $58.00 and gave the stock an “outperform” rating in a research note on Wednesday. Piper Sandler increased their target price on Scholar Rock from $51.00 to $58.00 and gave the stock an “overweight” rating in a report on Wednesday, March 4th. Raymond James Financial restated a “strong-buy” rating on shares of Scholar Rock in a research note on Tuesday, March 3rd. Finally, HC Wainwright reiterated a “buy” rating and set a $58.00 price target on shares of Scholar Rock in a research report on Tuesday, March 3rd. Four research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $54.93.

Scholar Rock Stock Performance

SRRK stock opened at $50.01 on Friday. The company has a 50 day moving average price of $45.22 and a 200 day moving average price of $40.75. Scholar Rock Holding Corporation has a fifty-two week low of $22.71 and a fifty-two week high of $50.50. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.95 and a quick ratio of 6.95. The stock has a market capitalization of $5.75 billion, a PE ratio of -14.58 and a beta of 0.68.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.10. During the same period in the prior year, the business earned ($0.64) earnings per share. Analysts forecast that Scholar Rock Holding Corporation will post -2.42 EPS for the current year.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).